Navigation Links
Detke Joins MedAvante as Chief Medical Officer
Date:3/12/2009

Former Eli Lilly executive Michael J. Detke, MD, PhD, is frequent presenter on the causes of failed clinical studies for central nervous system (CNS) therapeutics and methods for improvement

HAMILTON, N.J., March 12 /PRNewswire/ -- MedAvante, Inc. the leader in centralized psychiatric patient evaluation, announced today that Michael Detke, MD, PhD, has joined the company as Chief Medical Officer and Director of the MedAvante Research Institute. Dr. Detke comes to MedAvante from Eli Lilly, Inc., in Indianapolis, Indiana, where he was Executive Director and head of early phase development of CNS therapeutics.

"We are honored to have Michael join our team," says Paul Gilbert, Chief Executive Officer of MedAvante. "At Lilly, Mike led early phase development of one of the industry's deepest and strongest pipelines of CNS products. His earlier work on Cymbalta(R) and Prozac(R) proves that he is a top-caliber scientist dedicated to developing CNS therapeutics. At MedAvante, Mike will apply his leadership abilities, scientific expertise, and commitment to quality assurance to help us deliver our leading-edge methodology for removing sources of bias and variability, increasing signal detection, and reducing the high rate of failed CNS trials."

Dr. Detke says, "MedAvante holds great promise for ensuring the future success of CNS therapeutics. For decades and now acutely, our industry has struggled with the problems of rater bias and an inability to separate placebo response from active-drug response. MedAvante offers a potential powerful solution for these problems. Our methodology to substantially increase the efficiency of clinical studies can help bring new treatments to market for patients suffering from debilitating CNS diseases. Furthermore, it can help to elucidate efficacy further, to help patients and doctors understand, for example, the relative efficacy of different drugs for a disorder, or different doses of a drug."

Prior to joining MedAvante, Dr. Detke worked for Eli Lilly Research Laboratories in Indianapolis, for more than 8 years, most recently as Executive Director overseeing all CNS products in early phase development for psychiatry, neurology and pain indications. He is Associate Clinical Professor of Psychiatry at Indiana University School of Medicine, where he teaches and supervises medical students and residents in patient care. He is Research Associate at Harvard Medical School. He has been the principal investigator in numerous studies of CNS therapeutics. Dr. Detke has published more than 50 articles in peer-reviewed journals, and has served as a reviewer for numerous such journals. He is a member in prestigious scientific organizations such as ACNP and SOBP. He graduated summa cum laude with a BA and MS in Psychology at Yale University and his MD and PhD at the University of Pennsylvania; he completed his medical internship and psychiatry residency at Harvard University.

About MedAvante, Inc

MedAvante is a global provider of centralized expert psychological rating services to the pharmaceutical, biotechnology, and medical device industries. MedAvante is a pioneer in developing a solution for one of the most intractable problems in CNS clinical trials: the high rate of uninformative or failed studies. MedAvante applies unique methods to systematically remove potential sources of bias and variability from the assessment process. By centralizing assessments with expert, standardized, objective, clinical interviewers over MedAvante's two-way, real-time, high-quality videoconferencing, MedAvante makes subjective assessments of drug efficacy increasingly objective. As a result, sponsors can achieve increased study power and reduced trial-failure rates enabling them to bring more effective CNS drugs to market sooner. MedAvante operates facilities in Hamilton, New Jersey; Los Angeles, California; and Madison, Wisconsin. MedAvante is backed by over $34 million in investor financing including $20 Million in growth financing by Goldman Sachs and Trevi Health Ventures. For more information about MedAvante, visit www.medavante.net.


'/>"/>
SOURCE MedAvante, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Jocelyn Frederick Joins Tsoi/Kobus & Associates as Principal
2. Michael J. Fox Foundation Joins Effort to Recruit 10,000 People With Parkinsons Disease to New Web-Based PD Research Community
3. Veteran Rehab Specialist, James Conwell, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania
4. KevinMD.com Joins the HCPLive.com Network
5. Rehab Specialist, Michael Fisher, Joins Fast - Growing Alliance Seating & Mobility in North Carolina
6. Nurse & Veteran Rehab Specialist, Terri Witten, Joins Fast-Growing Alliance Seating & Mobility in Ohio
7. Veteran Rehab Specialist, Donna Cole, Joins Fast-Growing Alliance Seating & Mobility in California
8. Veteran Rehab Specialist, David Glancy, Joins Fast-Growing Alliance Seating & Mobility in Michigan
9. Wound Management Technologies Joins IMCO Vendor Network to Expand Sales Nationwide
10. Michael Forte Joins CONNEXION Healthcare as Chief Operations Officer
11. Julie Gallagher Joins Akerman Senterfitts Healthcare Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: